Cargando…
伊布替尼联合CAR-T治疗BCL-2抑制剂耐药伴del(17p)慢性淋巴细胞白血病一例报告并文献复习
OBJECTIVE: To improve the knowledge and experience of ibrutinib combined with CAR-T cells in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) with TP53 gene aberration. METHODS: One case of del (17p) CLL patients with BCL-2 inhibitor resist...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342441/ https://www.ncbi.nlm.nih.gov/pubmed/31648477 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.09.008 |